News
In PD-1/PD-L1 immune checkpoint inhibitor cancer treatment, IFN-γ is a prognostic marker. The production of IFN-γ is associated with an improved response to immune checkpoint blockade (ICB ...
in terms of IFN-γ production, was seen when ABL403 was tested in combination with the following immune-regulating antibodies: anti-4-1BB (urelumab), anti-PD-1 (pem-brolizumab) and anti-PD-L1 ...
Abstracts are available on the EASL Congress 2025 website at https://www.easlcongress.eu/. The posters are expected to be ...
In Mycobacterium abscessus complex pulmonary disease, elevated levels of IFN-γ and IL-17F may signal higher risk for disease ...
The use of Trodelvy plus Keytruda in patients with previously untreated PD-L1+ metastatic TNBC is investigational, and the safety and efficacy of this use have not been established. The ...
like anti-CTLA-4 and anti-PD-1/L1," Shi said. More information: Hongxing Shen et al, HIF1α-regulated glycolysis promotes activation-induced cell death and IFN-γ induction in hypoxic T cells ...
AB-101 (Oral PD-L1 Inhibitor): The Phase 1a/1b trial showed ... mL who were treated with 48 weeks of imdusiran and 24 weeks of IFN,” said Michael J. McElhaugh, Interim President and CEO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results